AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

Expectations for the full year Core tax rate are unchanged at 18-22% Core EPS increased 21% to $2.49 Five positive Phase III readouts and 13 approvals in major regions since the prior results Pascal ...

AstraZeneca posted increased core earnings per share and sales for the first quarter but warned of mounting legal challenges in China.

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca said today it may face a fine of up to $8m over suspected unpaid import taxes in China as the drugmaker works to ...

AstraZeneca’s AZN first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.10. Core earnings of $2.49 per share rose 21% year over year on ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

Despite AstraZeneca’s falling share price today, this writer believes the London-listed pharmaceutical giant could be worth a ...